Eton Pharmaceuticals Launches ET-900 Program for Epileptic Spasms

What happened

Eton Pharmaceuticals launched ET-900 to evaluate mecasermin, also called IGF-1, for infantile and epileptic spasms. It licensed Baylor College of Medicine patent rights and submitted a research application for an investigator-led Phase 2 study, with initial enrollment and dosing targeted for Q1 2027.

Confirmed

Global impact / market context

The program could create a future use for Eton’s mecasermin and support potential revenue if studies establish safety and benefit and regulators approve it. For now, the medicine is not approved for spasms, and its safety and effectiveness for these uses remain unestablished.

Analyst inference

The planned study may enroll up to 20 children ages 2–18 at three sites, while animal research reported fewer spasms. Those early findings do not establish results in people, so the program remains an uncertain, early-stage development effort.

Analyst inference

What to watch

1. Whether the investigator-sponsored Phase 2 study begins enrolling and dosing children in Q1 2027, as targeted, and whether its planned sites and enrollment proceed. Confirmed
2. Human study results on safety and changes in spasms, which will show whether the animal findings translate to children treated with mecasermin. Analyst inference
3. Any further development or regulatory updates for ET-900, since approval for spasms would be needed before Eton could market mecasermin for this use. Analyst inference

Evidence

• Original source link unavailable